|
AstraZeneca PLC on Friday said it will establish a new global strategic research & development centre in Beijing. The Cambridge, England-based pharmaceutical company said it will invest $2.5 billion in China’s capital to establish its sixth global strategic R&D centre alongside other major research and manufacturing agreements that will advance life sciences in China. AstraZeneca expects its workforce in China to increase to 1,700 employees. Chief Executive Officer Pascal Soriot said: ‘This $2.5 billion investment reflects our belief in the world-class life sciences ecosystem in Beijing, the extensive opportunities that exist for collaboration and access to talent, and our continued commitment to China. Our sixth strategic R&D centre will partner with the cutting-edge biology and AI science in Beijing and be a critical part of our global efforts to bring innovative medicines to patients worldwide.’ The company is establishing new R&D collaborations in Beijing, such as a strategic partnership with the Beijing Cancer Hospital in translational research, data science, and clinical development. Further, AstraZeneca is signing two collaboration and licensing deals, one with Harbour BioMed to discover multi-specific antibodies, and one with Syneron Bio to develop macro-cyclic peptides. Finally, AstraZeneca is launching a new joint venture with BioKangtai, aimed at developing, manufacturing and commercialising innovative vaccines for respiratory and other infections diseases for patients in China and around the world. It will be AstraZeneca’s first and only vaccine manufacturing facility in China, located in Beijing BioPark. AstraZeneca shares were down 1.1% to 11,676.00 pence each on Friday morning in London, giving it a market capitalisation of £181.04 billion. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
